Recent Investment Analysts’ Ratings Updates for Jazz Pharmaceuticals (JAZZ)

Jazz Pharmaceuticals (NASDAQ: JAZZ) has recently received a number of price target changes and ratings updates:

• 11/3/2026 – Jazz Pharmaceuticals had its price target raised by JPMorgan Chase & Co. from $300.00 to $310.00. They now have an “overweight” rating on the stock.
• 11/3/2026 – Jazz Pharmaceuticals had its price target raised by Morgan Stanley from $314.00 to $319.00. They now have an “overweight” rating on the stock.
• 11/3/2026 – Jazz Pharmaceuticals had its price target raised by Barclays from $271.00 to $275.00. They now have an “overweight” rating on the stock.
• 11/3/2026 – Jazz Pharmaceuticals had its price target raised by Royal Bank Of Canada from $296.00 to $305.00. They now have an “outperform” rating on the stock.
• 10/28/2026 – Jazz Pharmaceuticals was downgraded by Weiss Ratings from “buy (b-)” to “hold (c+)”.
• 10/28/2026 – Jazz Pharmaceuticals had its price target raised by JPMorgan Chase & Co. from $276.00 to $300.00. They now have an “overweight” rating on the stock.
• 10/21/2026 – Jazz Pharmaceuticals had its price target lowered by Morgan Stanley from $322.00 to $314.00. They now have an “overweight” rating on the stock.
• 10/8/2026 – Jazz Pharmaceuticals had its price target lowered by Royal Bank Of Canada from $299.00 to $296.00. They now have an “outperform” rating on the stock.
• 10/7/2026 – Jazz Pharmaceuticals had its price target raised by Truist Financial from $281.00 to $286.00. They now have a “buy” rating on the stock.
• 10/3/2026 – Jazz Pharmaceuticals was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 9/30/2026 – Jazz Pharmaceuticals is now covered by Citigroup. They set a “buy” rating and a $325.00 price target on the stock.
• 9/24/2026 – Jazz Pharmaceuticals is now covered by The Goldman Sachs Group. They set a “buy” rating and a $337.00 price target on the stock.
• 9/24/2026 – Jazz Pharmaceuticals is now covered by The Goldman Sachs Group. They set a “buy” rating and a $337.00 price target on the stock.
• 9/11/2026 – Jazz Pharmaceuticals had its price target raised by UBS Group from $315.00 to $337.00. They now have a “buy” rating on the stock.
• 9/10/2026 – Jazz Pharmaceuticals had its price target raised by Barclays from $270.00 to $271.00. They now have an “overweight” rating on the stock.

Jazz Pharmaceuticals Stock Performance

NASDAQ JAZZ traded up $4.41 during trading hours on Wednesday, reaching $234.15. The company’s stock had a trading volume of 565,564 shares, compared to its average volume of 932,826. The company has a current ratio of 1.78, a quick ratio of 1.58 and a debt-to-equity ratio of 0.69. The business has a 50-day simple moving average of $230.67 and a 200 day simple moving average of $216.80. Jazz Pharmaceuticals PLC has a 52 week low of $128.80 and a 52 week high of $266.38. The stock has a market cap of $15.20 billion, a PE ratio of 79.64, a PEG ratio of 0.43 and a beta of 0.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) EPS for the quarter, beating the consensus estimate of ($4.04) by $0.16. The company had revenue of $1.24 billion during the quarter, compared to analyst estimates of $1.21 billion. Jazz Pharmaceuticals had a return on equity of 16.55% and a net margin of 4.37%. The business’s revenue was up 10.4% compared to the same quarter last year. During the same period in the prior year, the company earned $8.13 earnings per share. Equities research analysts predict that Jazz Pharmaceuticals PLC will post 10.87 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Bruce C. Cozadd sold 6,000 shares of the business’s stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $250.13, for a total transaction of $1,500,780.00. Following the completion of the transaction, the director owned 351,875 shares of the company’s stock, valued at approximately $88,014,493.75. The trade was a 1.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Renee D. Gala sold 2,000 shares of the company’s stock in a transaction dated Tuesday, October 6th. The stock was sold at an average price of $236.40, for a total transaction of $472,800.00. Following the transaction, the chief executive officer owned 141,394 shares of the company’s stock, valued at $33,425,541.60. This represents a 1.39% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 94,121 shares of company stock valued at $23,337,922 in the last 90 days. Corporate insiders own 4.10% of the company’s stock.

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.

Jazz’s sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.